WO1998055495B1 - Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof - Google Patents
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereofInfo
- Publication number
- WO1998055495B1 WO1998055495B1 PCT/US1998/011578 US9811578W WO9855495B1 WO 1998055495 B1 WO1998055495 B1 WO 1998055495B1 US 9811578 W US9811578 W US 9811578W WO 9855495 B1 WO9855495 B1 WO 9855495B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunomodulatory
- immune response
- immunomodulatory composition
- iss
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT98926311T ATE252596T1 (en) | 1997-06-06 | 1998-06-05 | IMMUNO-STIMULATING OLIGONUCLEOTIDES, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF |
AU78178/98A AU753172B2 (en) | 1997-06-06 | 1998-06-05 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
CA2291483A CA2291483C (en) | 1997-06-06 | 1998-06-05 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP98926311A EP0986572B2 (en) | 1997-06-06 | 1998-06-05 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
JP50288499A JP4101888B2 (en) | 1997-06-06 | 1998-06-05 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
DE69819150T DE69819150T3 (en) | 1997-06-06 | 1998-06-05 | IMMUNOSTIMULATING OLIGONUCLEOTIDES, COMPOSITIONS THEREOF, AND METHOD OF USE THEREOF |
HK00102617A HK1024701A1 (en) | 1997-06-06 | 2000-04-29 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4879397P | 1997-06-06 | 1997-06-06 | |
US60/048,793 | 1997-06-06 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998055495A2 WO1998055495A2 (en) | 1998-12-10 |
WO1998055495A3 WO1998055495A3 (en) | 1999-05-27 |
WO1998055495B1 true WO1998055495B1 (en) | 1999-07-22 |
Family
ID=21956478
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011578 WO1998055495A2 (en) | 1997-06-06 | 1998-06-05 | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
PCT/US1998/011391 WO1998055609A1 (en) | 1997-06-06 | 1998-06-05 | Inhibitors of dna immunostimulatory sequence activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011391 WO1998055609A1 (en) | 1997-06-06 | 1998-06-05 | Inhibitors of dna immunostimulatory sequence activity |
Country Status (13)
Country | Link |
---|---|
US (4) | US6225292B1 (en) |
EP (3) | EP1003850B1 (en) |
JP (2) | JP4280309B2 (en) |
AT (2) | ATE252596T1 (en) |
AU (2) | AU755322B2 (en) |
CA (2) | CA2291483C (en) |
CY (1) | CY1109287T1 (en) |
DE (2) | DE69819150T3 (en) |
DK (1) | DK1003850T3 (en) |
ES (1) | ES2326848T3 (en) |
HK (1) | HK1024701A1 (en) |
PT (1) | PT1003850E (en) |
WO (2) | WO1998055495A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US8691209B2 (en) | 2001-09-14 | 2014-04-08 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US8815817B2 (en) | 2008-05-15 | 2014-08-26 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
US8871732B2 (en) | 2002-12-23 | 2014-10-28 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US8962579B2 (en) | 2007-10-26 | 2015-02-24 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9200042B2 (en) | 2006-03-07 | 2015-12-01 | Vaxinnate Corporation | Flagellin fusion proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
ATE355375T1 (en) | 1996-01-04 | 2006-03-15 | Novartis Vaccines & Diagnostic | BACTERIOFERRITIN FROM HELICOBACTER PYLORI |
ES2241042T3 (en) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
EP1003850B1 (en) * | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
AU757175B2 (en) * | 1997-09-05 | 2003-02-06 | Regents Of The University Of California, The | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
SI1077722T1 (en) * | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Methods and products for inducing mucosal immunity |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
PT1104306E (en) | 1998-08-10 | 2006-05-31 | Antigenics Inc | CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS |
WO2000021556A1 (en) * | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
PT1154790E (en) * | 1999-02-26 | 2005-03-31 | Chiron Srl | REFORCO OF THE ACTIVITY BACTERICIDE OF ANTIGEN AGAINST NEISSERIA WITH OLIGONUCLEOTIDOS CONTAINING REASONS CG |
GB2348132B (en) * | 1999-03-02 | 2004-08-04 | Nedaa Abdul-Ghani Nasif | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
WO2000054803A2 (en) * | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU4343700A (en) * | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
US6737066B1 (en) | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
OA11937A (en) * | 1999-05-06 | 2006-04-12 | Immune Response Corp Inc | HIV immunogenic compositions and methods. |
DE60041335D1 (en) * | 1999-08-19 | 2009-02-26 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOSTIMULATING SEQUENCES AND COMPOSITIONS THEREFOR |
CN100368020C (en) * | 1999-08-27 | 2008-02-13 | 不列颠哥伦比亚大学 | Compositions for stimulating cytokine secretion and inducing an immune response |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ES2564463T3 (en) | 1999-10-29 | 2016-03-22 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP1322655B1 (en) * | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020107212A1 (en) * | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
TR200302015T4 (en) | 2000-06-08 | 2004-01-21 | Intercell Biomedizinische Forschungs-Und Entwicklungs Ag | Immunostimulatory oligodeoxynucleotides |
WO2002016549A2 (en) * | 2000-08-25 | 2002-02-28 | Yeda Research And Development Co. Ltd. | METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
WO2002069369A2 (en) * | 2000-12-08 | 2002-09-06 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
CA2448031A1 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
EP2842964A1 (en) | 2001-06-05 | 2015-03-04 | Curevac GmbH | Virtual method of determining a modified mRNA sequence |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
AU2002326561B2 (en) * | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
AU2002362019B2 (en) * | 2001-11-21 | 2007-12-20 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy |
DE10162480A1 (en) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | The application of mRNA for use as a therapeutic agent against tumor diseases |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
JP4646516B2 (en) | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Fine particles with adsorbed polypeptide-containing molecules |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
DE10229872A1 (en) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immune stimulation through chemically modified RNA |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
JP2005532067A (en) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid composition for stimulating immune response |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
KR20050042134A (en) * | 2002-07-15 | 2005-05-04 | 길리애드 사이언시즈, 인코포레이티드 | Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
SG172476A1 (en) | 2002-08-12 | 2011-07-28 | Dynavax Tech Corp | Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
SI2241325T1 (en) | 2002-10-29 | 2012-05-31 | Coley Pharm Group Inc | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
JP4976653B2 (en) * | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides |
EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
US7811813B2 (en) | 2002-11-21 | 2010-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
WO2004053104A2 (en) * | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
NZ541027A (en) | 2002-12-23 | 2008-04-30 | Dynavax Tech Corp | Immunostimulatory sequence oligonucleotides and methods of using the same |
WO2004058159A2 (en) | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
CA2513655C (en) | 2003-01-21 | 2011-11-22 | Chiron Corporation | Use of tryptanthrin compounds for immune potentiation |
JP4976848B2 (en) | 2003-02-20 | 2012-07-18 | ユニバーシティー オブ コネティカット ヘルス センター | Methods and compositions for the treatment of cancer and infectious diseases using alpha (2) macroglobulin-antigen molecule complexes |
NZ542323A (en) | 2003-03-26 | 2008-07-31 | Cytos Biotechnology Ag | Melan-A peptide analogue-virus-like-particle conjugates |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
EP1608403A2 (en) * | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
WO2004110353A2 (en) * | 2003-05-15 | 2004-12-23 | The Board Of Trustees Of The Leland Stanford Junior University | Novel immunomodulating peptide |
WO2004100965A1 (en) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | Immunostimulant |
ES2596553T3 (en) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
JP3976742B2 (en) | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | Immunostimulatory oligonucleotides that induce interferon alpha |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
ES2543207T3 (en) | 2004-09-01 | 2015-08-17 | Dynavax Technologies Corporation | Methods and compositions for the inhibition of innate immune responses and autoimmunity |
JP2008000001A (en) * | 2004-09-30 | 2008-01-10 | Osaka Univ | Immune stimulating oligonucleotide and use in pharmaceutical |
US20060135906A1 (en) * | 2004-11-16 | 2006-06-22 | Akihiko Matsumura | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
CA2591582A1 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
CN101107007B (en) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CA2598992A1 (en) * | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
CN101171033A (en) | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
JP2008535862A (en) * | 2005-04-08 | 2008-09-04 | キメリクス,インコーポレイテッド | Compounds, compositions and methods for the treatment of poxvirus infections |
US20070083186A1 (en) * | 2005-09-30 | 2007-04-12 | Darrick Carter | Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles |
KR20080066712A (en) * | 2005-09-30 | 2008-07-16 | 티티아이 엘뷰 가부시키가이샤 | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
WO2007040938A1 (en) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau, Inc. | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
JP2009525048A (en) * | 2006-02-01 | 2009-07-09 | ザ ジョンズ ホプキンス ユニバーシティー | Polypeptide-nucleic acid complex for immunological prophylaxis or immunotherapy against neoplastic disorders or infections |
CA2642152C (en) * | 2006-02-15 | 2016-11-01 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
DK2034015T3 (en) | 2006-05-31 | 2012-10-15 | Toray Industries | Immunostimulatory oligonucleotide and its pharmaceutical use |
MX2008015529A (en) | 2006-06-12 | 2009-01-13 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages. |
CA2655327A1 (en) * | 2006-06-13 | 2007-12-21 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
DE102006035618A1 (en) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | New nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria |
JP2010507361A (en) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn as an immunostimulant / adjuvant |
CN104857512A (en) | 2006-11-09 | 2015-08-26 | 戴纳瓦克斯技术公司 | Long Term Disease Modification Using Immunostimulatory Oligonucleotides |
WO2009018500A1 (en) * | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
JP5563455B2 (en) * | 2007-08-01 | 2014-07-30 | イデラ ファーマシューティカルズ インコーポレイテッド | Novel synthetic agonist of TLR9 |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
PT2222697E (en) | 2007-11-01 | 2013-02-15 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
MX2010008148A (en) * | 2008-01-25 | 2010-10-20 | Chimerix Inc | Methods of treating viral infections. |
ES2557282T3 (en) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use |
ES2594102T3 (en) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutants by flagelin deletion and methods for its use |
GB0809476D0 (en) * | 2008-05-23 | 2008-07-02 | Cambridge Entpr Ltd | Treatment of neurodegenerative disorders |
EP3552625A1 (en) | 2008-06-27 | 2019-10-16 | Zoetis Services LLC | Novel adjuvant compositions |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
CN102245198B (en) | 2008-12-09 | 2016-08-17 | 辉瑞疫苗有限责任公司 | IgE CH3 peptide vaccine |
BRPI1005670A8 (en) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | adjuvant compositions and processes of use. |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
HUE037416T2 (en) | 2009-09-03 | 2018-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
CN102640001A (en) | 2009-11-05 | 2012-08-15 | 诺瓦提斯公司 | Biomarkers predictive of progression of fibrosis |
CN102762224A (en) | 2009-12-22 | 2012-10-31 | 塞尔德克斯医疗公司 | Vaccine compositions |
EA201290876A1 (en) | 2010-03-05 | 2013-03-29 | Президент Энд Феллоуз Оф Гарвард Колледж | COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE |
BR122021020829B8 (en) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | NON-NATURALLY OCCURRING FACTOR H-BINDING PROTEIN (FHBP), COMPOSITION, AND GENETICALLY MODIFIED NEISSERIA MENINGITIDIS HOST CELL |
EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | Methods of treating retroviral infections and related dosage regimes |
CA2798837A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
KR101810593B1 (en) | 2010-06-16 | 2017-12-22 | 다이나박스 테크놀로지 코퍼레이션 | Methods of treatment using tlr7 and/or tlr9 inhibitors |
DK2449113T3 (en) | 2010-07-30 | 2016-01-11 | Curevac Ag | Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US9228184B2 (en) | 2012-09-29 | 2016-01-05 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
US9868955B2 (en) | 2012-09-29 | 2018-01-16 | Dynavax Technologies Corporation | Human toll-like receptor inhibitors and methods of use thereof |
JP2016507520A (en) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Stabilized hepatitis B core polypeptide |
AU2014236340B2 (en) | 2013-03-14 | 2019-01-17 | Massachusetts Institute Of Technology | Nanoparticle-based compositions |
EP2970364B1 (en) | 2013-03-14 | 2019-04-24 | Andes Biotechnologies Global, Inc. | Methods for detecting and treating multiple myeloma |
CA2906198C (en) | 2013-03-14 | 2022-11-29 | Andes Biotechnologies S.A. | Antisense oligonucleotides for treatment of cancer stem cells |
US10669547B2 (en) | 2013-03-15 | 2020-06-02 | Kambiz Shekdar | Genome editing using effector oligonucleotides for therapeutic treatment |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2909586C (en) | 2013-05-15 | 2021-08-31 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
WO2015024668A2 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Respiratory syncytial virus (rsv) vaccine |
EP3049105B1 (en) | 2013-09-19 | 2020-12-30 | Moredun Research Institute | Vaccine |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
CA2928908C (en) | 2013-11-01 | 2021-01-12 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
EP3129050A2 (en) | 2014-04-01 | 2017-02-15 | CureVac AG | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
CN114699518A (en) | 2015-01-16 | 2022-07-05 | 硕腾服务有限责任公司 | Foot and mouth disease vaccine |
AU2016271018A1 (en) | 2015-05-29 | 2017-11-30 | Dynavax Technologies Corporation | Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer |
WO2017125844A1 (en) | 2016-01-19 | 2017-07-27 | Pfizer Inc. | Cancer vaccines |
CN109451729B (en) * | 2016-06-08 | 2022-03-22 | 哈佛学院院长及董事 | Engineered viral vectors reduce induction of inflammation and immune responses |
BR112019009469A2 (en) | 2016-11-09 | 2019-07-30 | Pulmotect Inc | methods and compositions for adaptive immune modulation |
AU2018364542A1 (en) * | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
CN117441103A (en) | 2021-03-16 | 2024-01-23 | 国立大学法人大阪大学 | Novel medical technology using follicular T cells |
CN117425668A (en) | 2021-03-16 | 2024-01-19 | 国立大学法人大阪大学 | SARS-CoV-2 virus specific follicular helper T cell Tfh |
WO2023081486A1 (en) | 2021-11-08 | 2023-05-11 | Nurix Therapeutics, Inc. | Toll-like receptor therapy combinations with cbl-b inhibitor compounds |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1234718A (en) | 1914-03-21 | 1917-07-31 | Int Harvester Canada | Buckle. |
US2811896A (en) | 1953-10-05 | 1957-11-05 | Welsh Mfg Co | Ophthalmic mounting |
US3725545A (en) | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4425732A (en) | 1981-06-17 | 1984-01-17 | Kania Tadeusz E | Animal trap |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
DE3583564D1 (en) * | 1984-08-23 | 1991-08-29 | Hans Joachim Wolf | DNA SEQUENCES OF THE EBV GENOME, RECOMBINANT DNA MOLECULES, METHOD FOR THE PRODUCTION OF EBV-RELATED ANTIGENS, DIAGNOSTIC COMPOSITIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME ANTIGENS. |
US5110906A (en) * | 1986-08-21 | 1992-05-05 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5268365A (en) | 1988-03-11 | 1993-12-07 | Rudolph Frederick B | Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5218103A (en) | 1988-05-26 | 1993-06-08 | University Patents, Inc. | Nucleoside thiophosphoramidites |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5331090A (en) * | 1989-09-08 | 1994-07-19 | California Institute Of Biological Research | CR2 ligand compositions and methods for modulating immune cell functions |
WO1991003251A1 (en) * | 1989-09-08 | 1991-03-21 | California Institute Of Biological Research | Cr2 ligand compositions and methods for modulating immune cell functions |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
EP0527818A4 (en) | 1990-04-30 | 1993-09-15 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of arachidonic acid metabolism |
EP0468520A3 (en) * | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5286365A (en) | 1992-01-15 | 1994-02-15 | Beckman Instruments, Inc. | Graphite-based solid state polymeric membrane ion-selective electrodes |
ES2123062T3 (en) | 1992-08-21 | 1999-01-01 | Biogen Inc | TRANSPORTATION POLYPEPTIDES DERIVED FROM TAT PROTEIN. |
US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5552390A (en) * | 1993-12-09 | 1996-09-03 | The Board Of Regents Of The University Of Nebraska | Phosphorothioate inhibitors of metastatic breast cancer |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5665347A (en) * | 1995-02-02 | 1997-09-09 | Genetics Institute | IL-12 inhibition of B1 cell activity |
US5968909A (en) * | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
EP0929668A1 (en) * | 1996-09-04 | 1999-07-21 | Onyx Pharmaceuticals, Inc. | Modulators of brca1 activity |
ES2241042T3 (en) * | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
EP0983289A4 (en) * | 1997-05-19 | 2001-04-25 | Merck & Co Inc | Oligonucleotide adjuvant |
US6613881B1 (en) * | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP1003850B1 (en) * | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
KR20030070092A (en) | 2001-01-04 | 2003-08-27 | 바스큘라 바이오제닉스 리미티드 | Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
WO2003022296A1 (en) * | 2001-09-07 | 2003-03-20 | The Trustees Of Boston University | Method and composition for treating immune complex associated disorders |
US7811813B2 (en) * | 2002-11-21 | 2010-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
CA2655327A1 (en) * | 2006-06-13 | 2007-12-21 | Bayhill Therapeutics, Inc. | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
-
1998
- 1998-06-05 EP EP98926229A patent/EP1003850B1/en not_active Expired - Lifetime
- 1998-06-05 US US09/092,314 patent/US6225292B1/en not_active Expired - Lifetime
- 1998-06-05 PT PT98926229T patent/PT1003850E/en unknown
- 1998-06-05 DE DE69819150T patent/DE69819150T3/en not_active Expired - Lifetime
- 1998-06-05 ES ES98926229T patent/ES2326848T3/en not_active Expired - Lifetime
- 1998-06-05 JP JP50280399A patent/JP4280309B2/en not_active Expired - Lifetime
- 1998-06-05 EP EP09005807A patent/EP2085090A3/en not_active Withdrawn
- 1998-06-05 WO PCT/US1998/011578 patent/WO1998055495A2/en active IP Right Grant
- 1998-06-05 JP JP50288499A patent/JP4101888B2/en not_active Expired - Lifetime
- 1998-06-05 DK DK98926229T patent/DK1003850T3/en active
- 1998-06-05 EP EP98926311A patent/EP0986572B2/en not_active Expired - Lifetime
- 1998-06-05 CA CA2291483A patent/CA2291483C/en not_active Expired - Lifetime
- 1998-06-05 CA CA002293489A patent/CA2293489C/en not_active Expired - Fee Related
- 1998-06-05 WO PCT/US1998/011391 patent/WO1998055609A1/en active IP Right Grant
- 1998-06-05 AU AU78113/98A patent/AU755322B2/en not_active Ceased
- 1998-06-05 AT AT98926311T patent/ATE252596T1/en not_active IP Right Cessation
- 1998-06-05 DE DE69840850T patent/DE69840850D1/en not_active Expired - Lifetime
- 1998-06-05 AT AT98926229T patent/ATE432348T1/en active
- 1998-06-05 AU AU78178/98A patent/AU753172B2/en not_active Expired
-
2000
- 2000-04-29 HK HK00102617A patent/HK1024701A1/en not_active IP Right Cessation
-
2001
- 2001-01-25 US US09/770,943 patent/US20020086839A1/en not_active Abandoned
-
2009
- 2009-08-03 CY CY20091100815T patent/CY1109287T1/en unknown
-
2010
- 2010-02-01 US US12/697,917 patent/US20110034541A1/en not_active Abandoned
- 2010-08-24 US US12/862,429 patent/US8729039B2/en not_active Expired - Fee Related
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8372413B2 (en) | 2000-12-27 | 2013-02-12 | Dynavax Technologies Corporation | Immunomodulatory polynucleotides and methods of using the same |
US9028845B2 (en) | 2001-06-21 | 2015-05-12 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same-IV |
US8691209B2 (en) | 2001-09-14 | 2014-04-08 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
US8871732B2 (en) | 2002-12-23 | 2014-10-28 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US9422564B2 (en) | 2002-12-23 | 2016-08-23 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US9200042B2 (en) | 2006-03-07 | 2015-12-01 | Vaxinnate Corporation | Flagellin fusion proteins |
US9476053B2 (en) | 2007-10-26 | 2016-10-25 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
US8962579B2 (en) | 2007-10-26 | 2015-02-24 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
US8815817B2 (en) | 2008-05-15 | 2014-08-26 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
US9504742B2 (en) | 2009-03-25 | 2016-11-29 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9186400B2 (en) | 2009-03-25 | 2015-11-17 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
US9765100B2 (en) | 2010-02-12 | 2017-09-19 | Chimerix, Inc. | Nucleoside phosphonate salts |
US9447164B2 (en) | 2010-08-06 | 2016-09-20 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9334328B2 (en) | 2010-10-01 | 2016-05-10 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9533047B2 (en) | 2011-03-31 | 2017-01-03 | Modernatx, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9271996B2 (en) | 2011-12-16 | 2016-03-01 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9186372B2 (en) | 2011-12-16 | 2015-11-17 | Moderna Therapeutics, Inc. | Split dose administration |
US9295689B2 (en) | 2011-12-16 | 2016-03-29 | Moderna Therapeutics, Inc. | Formulation and delivery of PLGA microspheres |
US9220792B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding aquaporin-5 |
US9192651B2 (en) | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9233141B2 (en) | 2012-04-02 | 2016-01-12 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9301993B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding apoptosis inducing factor 1 |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9220755B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders |
US9221891B2 (en) | 2012-04-02 | 2015-12-29 | Moderna Therapeutics, Inc. | In vivo production of proteins |
US9216205B2 (en) | 2012-04-02 | 2015-12-22 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding granulysin |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
US9149506B2 (en) | 2012-04-02 | 2015-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding septin-4 |
US9114113B2 (en) | 2012-04-02 | 2015-08-25 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding citeD4 |
US9107886B2 (en) | 2012-04-02 | 2015-08-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding basic helix-loop-helix family member E41 |
US9095552B2 (en) | 2012-04-02 | 2015-08-04 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9675668B2 (en) | 2012-04-02 | 2017-06-13 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding hepatitis A virus cellular receptor 2 |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998055495B1 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
DE69733020T2 (en) | IMMUNOSTIMULATING OLIGONUCLEOTIDE CONJUGATES | |
Illum et al. | Chitosan as a novel nasal delivery system for vaccines | |
Alpar et al. | Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery | |
DE60109443T2 (en) | ANTIGENIC COMPOSITION CONTAINING A POLYCAPIC PEPTIDE AND INOSIN AND CYTOSINE | |
Sulczewski et al. | Nanoparticle vaccines against viral infections | |
O'Hagan et al. | Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles | |
Magiri et al. | Recent advances in experimental polyphosphazene adjuvants and their mechanisms of action | |
Tomai et al. | TLR7/8 agonists as vaccine adjuvants | |
CA2295237A1 (en) | Antigen delivery system comprising monoglyceride or diglyceride derivatives as adjuvant | |
JP2002500159A5 (en) | ||
CA2297101A1 (en) | Receptor specific transepithelial transport of therapeutics | |
BR0312935A (en) | Virus-like particle, mutein, vectors for producing said particle and recombinant protein, composition, process for producing antigen repeat and order row, nucleic acid molecule, host cell, method for producing said particle and use of vaccine composition | |
IE910268A1 (en) | Liposome-containing intranasal vaccine formulation | |
US7767197B2 (en) | Delivery vehicle composition and methods for delivering antigens and other drugs | |
JP2002526425A (en) | Methods and adjuvants for stimulating mucosal immunity | |
EP2543387A1 (en) | Mucosal vaccine | |
Cahn et al. | Biomaterials for intranasal and inhaled vaccine delivery | |
JP6797022B2 (en) | Vaccine delivery system using yeast cell wall particles | |
JP2004504260A5 (en) | ||
Carcaboso et al. | Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration | |
EP2026820A1 (en) | Compositions comprising chitin microparticles and their medical uses | |
US20020197321A1 (en) | Solid dispersing vaccine composition for oral delivery | |
Saini et al. | Polymeric lamellar substrate particles as carrier adjuvant for recombinant hepatitis B surface antigen vaccine | |
AU768178B2 (en) | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2291483 Country of ref document: CA Ref country code: CA Ref document number: 2291483 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1999 502884 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998926311 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 78178/98 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1998926311 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 78178/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998926311 Country of ref document: EP |